Shape Therapeutics Unveils AAVidâ„¢ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy

▴ Shape Therapeutics Unveils AAVidâ„¢ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
Shape Therapeutics, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.

Shape Therapeutics, Inc. a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.

The AAVidTM capsid discovery platform uses non-random mutational fitness to create massive capsid libraries of billions of unique AAV variants for direct-to-NHP in vivo biological selection. By combining cutting-edge DNA synthesis, advanced synthetic biology, next-generation sequence barcoding, and machine learning algorithms, ShapeTX generates industry-leading library size and diversity to enable the development of best-in-class human therapeutics.

 

“Wildtype first-generation AAVs are enabling the recent advances in gene therapy, but they have been plagued by toxicities in the clinic due in part to a lack of tissue specificity, resulting in the need for high doses. Our AAVidTM platform solves the issue by creating novel capsid variants with specific tissue-tropism,” said Francois Vigneault Ph.D., President, and CEO at ShapeTX. “We’ve stayed quiet for the past three years while developing a superior AAV platform technology and are excited to announce that we have best-in-class AAV variants in hand. Today, we are announcing our novel liver-tropic AAV5 variants – stay tuned for more to come.”

 

David J. Huss, Ph.D., Vice President and Head of Research added, “The vast structural space for exploration at the AAV capsid/target cell interface necessitates enormous library size and diversity, which until now, has only been probed with capsid library sizes in the tens of thousands to millions. At ShapeTX, we set out to create a superior AAV capsid discovery platform with library sizes in the billions of unique variants, thereby maximizing the opportunity for novel virus/target cell interactions.” Dr. Huss presented the details of the platform at the 2nd RNA Editing Summit on Dec. 2, 2020.

 

About Shape Therapeutics, Inc

Shape Therapeutics is a biotechnology company developing next-generation RNA-targeted therapies to treat the world’s most challenging diseases. The ShapeTX technology platform includes RNAskip™, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfixTM, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVidTM, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing life-long cures to patients. Shape Life!

Tags : #ShapeTherapeutics #GeneTherapyCompany #AAVidCapsid #AAVid #AAV5 #DavidJHuss #RNAfix #RNAskip

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024
Why the World Trusts Indian Pharmaceuticals for Life-Saving SolutionsDecember 20, 2024
International Tsunami Conference Concludes at AmritapuriDecember 20, 2024
Prestige Marks 75 Years of Revolutionizing Home Cooking with Iconic Innovative ProductsDecember 20, 2024
Revolutionizing Education: Online Learning Platforms Transforming Study Materials for Board and Competitive ExamsDecember 19, 2024
Why Your Blood Pressure Reading Might Be a Lie and How to Fix ItDecember 19, 2024
Vaccines, Cards, and Digital Records: How India is Fighting Healthcare InequalityDecember 19, 2024
Bridging Borders: Sri Lanka’s President Explores India’s Healthcare and HeritageDecember 19, 2024
Jeevan Jyoti Project Brings Eye Care to Alwar's Rural CommunitiesDecember 19, 2024
Crompton Launches New Range of Decorative Wall Lights Providing a Perfect Blend of Uniqueness & AestheticsDecember 19, 2024
Can One Injection End Decades of HIV Inequality?December 19, 2024
Multi-Organ Marvel: How a 12-Hour Surgery Gave a Businessman New LifeDecember 19, 2024
Jupiter Hospital Celebrates BMT Heroes: Honoring Patients, Donors, and Advancing Care with New MilestonesDecember 18, 2024
Beware of Fraudulent Activities in the Name of Asian HospitalDecember 17, 2024
Why Feeling Lonely Can Be as Dangerous as Smoking for Your BrainDecember 17, 2024
Rethinking Intelligence: How Brain Connectivity Defines Our Intellectual PotentialDecember 17, 2024
Lonely in a Crowd: When Socializing Fails to Heal Young MindsDecember 17, 2024
How many hours of sleep are children getting on average now compared to before the pandemic?December 17, 2024